Increase of prostate specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing [223Ra]RaCl2 therapy

Author:

Lu Hsi-Huei1,Chiu Nan-Tsing1,Tsai Mu-Hung1ORCID

Affiliation:

1. National Cheng Kung University Hospital

Abstract

Abstract Background [223Ra]RaCl2 is an important treatment modality for bone-dominant metastatic castration-resistant prostate cancer (mCRPC). However, there is currently a lack of effective markers to monitor treatment response during the course of treatment. We retrospectively collected data from mCRPC patients who underwent [223Ra]RaCl2 treatment at our institution between August 2020 and June 2023. Prostate specific antigen (PSA) measurements prior to treatment and during treatment were collected. Baseline PSADT was calculated from PSA measurements prior to [223Ra]RaCl2 treatment; interim PSADT was calculated from PSA measurements before [223Ra]RaCl2 treatment and prior to the 4th course injection. Overall survival was calculated from start of treatment to the date of death. Univariable and multivariable analysis using the Cox proportional hazards model were performed to examine the association of factors with overall survival. Results We included 35 patients from our institution, with a median overall survival of 13.3 months. Eighteen (51.4%) completed all six courses of treatment. PSADT response (interim PSADT > baseline PSADT or decreased PSA) was observed in 20 patients. Overall survival was associated with a PSADT response (HR = 0.318, 95% CI 0.133–0.762, p = 0.010) when compared to patients without a PSADT response. Conclusions Dynamic changes in PSADT were associated with survival in mCRPC patients receiving [223Ra]RaCl2 therapy. Comparing interim and baseline PSADT could serve as a valuable marker for determining treatment benefit.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3